TW202332438A - Ｐａｒｐ１抑制劑 - Google Patents

Ｐａｒｐ１抑制劑 Download PDF

Info

Publication number
TW202332438A
TW202332438A TW111149299A TW111149299A TW202332438A TW 202332438 A TW202332438 A TW 202332438A TW 111149299 A TW111149299 A TW 111149299A TW 111149299 A TW111149299 A TW 111149299A TW 202332438 A TW202332438 A TW 202332438A
Authority
TW
Taiwan
Prior art keywords
partially unsaturated
membered saturated
independently selected
group
nitrogen
Prior art date
Application number
TW111149299A
Other languages
English (en)
Chinese (zh)
Inventor
俊 潘
白瑀
鄭賀文
李鈺
之曄 楊
亮星 吳
文慶 姚
Original Assignee
美商思諾維新醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商思諾維新醫藥公司 filed Critical 美商思諾維新醫藥公司
Publication of TW202332438A publication Critical patent/TW202332438A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111149299A 2021-12-22 2022-12-21 Ｐａｒｐ１抑制劑 TW202332438A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163292903P 2021-12-22 2021-12-22
US63/292,903 2021-12-22
US202263327228P 2022-04-04 2022-04-04
US63/327,228 2022-04-04
US202263403459P 2022-09-02 2022-09-02
US63/403,459 2022-09-02

Publications (1)

Publication Number Publication Date
TW202332438A true TW202332438A (zh) 2023-08-16

Family

ID=85156997

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111149299A TW202332438A (zh) 2021-12-22 2022-12-21 Ｐａｒｐ１抑制劑

Country Status (14)

Country Link
US (1) US20250163022A1 (enExample)
EP (1) EP4452963A1 (enExample)
JP (1) JP2025501762A (enExample)
KR (1) KR20240136978A (enExample)
AU (1) AU2022420969A1 (enExample)
CA (1) CA3241875A1 (enExample)
CL (1) CL2024001874A1 (enExample)
CO (1) CO2024009571A2 (enExample)
CR (1) CR20240296A (enExample)
IL (1) IL313727A (enExample)
MX (1) MX2024007673A (enExample)
PE (1) PE20242004A1 (enExample)
TW (1) TW202332438A (enExample)
WO (1) WO2023122140A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL305262A (en) 2021-03-10 2023-10-01 Jnana Therapeutics Inc Small molecule inhibitors of mammalian SLC6A19 function
AU2023229992A1 (en) * 2022-03-11 2024-10-10 Impact Therapeutics (Shanghai), Inc. Substituted tricyclic compounds as parp inhibitors and the use thereof
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
AU2023299635A1 (en) * 2022-06-27 2025-01-02 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Tricyclic compounds and uses thereof
CN115232129B (zh) * 2022-08-18 2023-12-01 上海闻耐医药科技有限公司 一种parp1选择性抑制剂及其制备方法和用途
CN120092010A (zh) * 2022-11-02 2025-06-03 轩竹生物科技股份有限公司 多环类聚（adp核糖）聚合酶选择性抑制剂
AU2023378452A1 (en) * 2022-11-10 2025-06-19 Haihe Biopharma Co., Ltd. Fused tricyclic parp1 inhibitor, preparation method therefor, and use thereof
TW202506680A (zh) * 2023-04-28 2025-02-16 美商思諾維新醫藥公司 作為ｐａｒｐ１抑制劑之雜環化合物
CN119462669A (zh) * 2023-08-11 2025-02-18 上海海和药物研究开发股份有限公司 稠合三环类化合物、其药物组合物和用途
WO2025067417A1 (zh) * 2023-09-28 2025-04-03 成都赜灵生物医药科技有限公司 并内酰胺环类化合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541417B2 (en) * 2009-07-30 2013-09-24 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) polymerase (PARP) inhibitors
JPWO2015060348A1 (ja) * 2013-10-23 2017-03-09 大日本住友製薬株式会社 縮合ピラゾール誘導体
PT3312177T (pt) * 2015-06-09 2021-05-17 Onconic Therapeutics Inc Composto derivado tricíclico, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo
TWI837403B (zh) * 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物

Also Published As

Publication number Publication date
AU2022420969A1 (en) 2024-06-13
KR20240136978A (ko) 2024-09-19
US20250163022A1 (en) 2025-05-22
CO2024009571A2 (es) 2024-07-29
IL313727A (en) 2024-08-01
JP2025501762A (ja) 2025-01-23
CA3241875A1 (en) 2023-06-29
MX2024007673A (es) 2024-09-06
CL2024001874A1 (es) 2024-12-06
EP4452963A1 (en) 2024-10-30
WO2023122140A1 (en) 2023-06-29
PE20242004A1 (es) 2024-10-03
CR20240296A (es) 2024-09-18

Similar Documents

Publication Publication Date Title
JP7095052B2 (ja) Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法
WO2023122140A1 (en) Parp1 inhibitors
TWI891666B (zh) 作為ｆｇｆｒ抑制劑之雙環雜環
TWI917313B (zh) 參與協同結合之化合物及其用途
ES3060664T3 (en) Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
WO2020253862A1 (zh) 含氮芳基磷氧化物类衍生物、其制备方法和应用
JP2021521194A (ja) ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法
US20250215013A1 (en) Substituted tricyclic compounds as parp inhibitors and the use thereof
JP2016512239A (ja) Ａｔｒキナーゼの阻害剤として有用な化合物
TW201811799A (zh) 吡唑并嘧啶化合物及其用途
JP2016512816A (ja) Ａｔｒキナーゼの阻害剤として有用な化合物
JP2016512815A (ja) Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
KR20230107419A (ko) 암 치료 방법
KR20230068412A (ko) Cbp/ep300 브로모도메인 억제제로서의 헤테로시클릭 화합물
EP4359082A1 (en) Her2 mutation inhibitors
EP3398947A1 (en) Nitrogen-containing fused heterocyclic compound, as well as preparation method, intermediate, composition and application thereof
WO2025014877A2 (en) Triazolo wrn inhibitors
CN115636833A (zh) 作为ATM激酶选择性调节剂的取代的咪唑并[4,5-c]噌啉-2-酮化合物及其用途
CN110312717B (zh) 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用
CN121443294A (zh) Wrn抑制剂
KR20240102884A (ko) Her2 돌연변이 억제제
WO2023116865A1 (zh) 含吡唑类衍生物、其药学上可接受的盐及其制备方法和应用
TW202404968A (zh) ＰＩ３Ｋα抑制劑
CN117794940A (zh) 用作抗癌药剂的稠合杂芳基化合物
CN118696036A (zh) Parp1抑制剂